Testing for inherited Cowden syndrome looks for a harmful PTEN variant in a person’s germline DNA—the DNA present in most of their body’s cells and potentially passed to their children. Testing is often done using a blood or saliva sample. A clinician may order a test focused on PTEN or a broader genetic panel, depending on the person’s features and family history.

A result showing a harmful inherited PTEN variant can help confirm PHTS and guide medical care. It may also allow relatives to have targeted testing for the specific variant found in the family. A result that does not find a variant does not always explain every symptom or rule out a clinical diagnosis. The meaning depends on the test performed and the person’s history, so a clinical geneticist or genetic counselor should interpret it.

A PTEN change found by tumor testing is a different kind of result. Tumor testing examines DNA in cancer tissue, often to help guide treatment. Some changes arise only in the tumor during a person’s lifetime; these are called somatic changes. A somatic PTEN change does not, by itself, show that the person was born with the change or that relatives may have inherited it.

Tumor testing can sometimes detect a change that is also inherited. If a PTEN variant is found in tumor tissue, the treating team may recommend a separate test using blood or saliva to determine whether it is present in the germline. This is especially relevant when the person’s personal or family history suggests PHTS, or when knowing the inherited status could affect care for the person or their relatives.

Testing is most useful when it is chosen and interpreted with medical context. A genetic professional can review the person’s history, explain what the test can and cannot detect, and discuss possible results. These may include a harmful variant, no variant detected, or a variant of uncertain significance—a change for which there is not enough evidence to know whether it affects health. A variant of uncertain significance generally should not be treated as a confirmed diagnosis without further evidence.

If you are in India, the same basic distinction applies: ask whether the proposed test checks for an inherited variant in blood or saliva, or only analyzes tumor tissue. The laboratory’s turnaround time varies, so confirm it directly with the testing provider.